1388893-50-2

Basic information

• Product Name: trans-1-(pyrrolidin-1-yl)-2-[(4-[7-thia-9,11-diazatricyclo[6.4.0.0(2,6)]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yloxy]cyclohexyl)amino]ethan-1-one
• Synonyms: trans-1-(pyrrolidin-1-yl)-2-[(4-[7-thia-9,11-diazatricyclo[6.4.0.0(2,6)]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yloxy]cyclohexyl)amino]ethan-1-one
• CAS NO: 1388893-50-2
• Molecular Weight: 400.545
• Mol File: 1388893-50-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: trans-1-(pyrrolidin-1-yl)-2-[(4-[7-thia-9,11-diazatricyclo[6.4.0.0(2,6)]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yloxy]cyclohexyl)amino]ethan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: trans-1-(pyrrolidin-1-yl)-2-[(4-[7-thia-9,11-diazatricyclo[6.4.0.0(2,6)]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yloxy]cyclohexyl)amino]ethan-1-one(1388893-50-2)
• EPA Substance Registry System: trans-1-(pyrrolidin-1-yl)-2-[(4-[7-thia-9,11-diazatricyclo[6.4.0.0(2,6)]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yloxy]cyclohexyl)amino]ethan-1-one(1388893-50-2)

Safety Data

• Hazardous Substances Data: 1388893-50-2(Hazardous Substances Data)

Upstream product

• 1388890-61-6 2-[trans-4-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)hydroxycyclohexyl]isoindoline-1,3-dione 
• 1388891-81-3 tert-butyl N-(4-[7-thia-9,11-diazatricyclo[6.4.0.0(2,6)]dodeca-1⁽⁸⁾,2⁽⁶⁾,9,11-tetraen-12-yloxy]cyclohexyl)carbamate 
• 99337-98-1 2-((1R,4R)-4-hydroxycyclohexyl) isoindoline-1,3-dione 
• 300816-22-2 4-chloro-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidine 
• 20266-00-6 chloroacetic acid pyrrolidide 
• 1388890-58-1 trans-4-[(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)oxy]cyclohexanamine 
• 111300-06-2 trans-tert-butyl 4-hydroxycyclohexylcarbamate 
• 27489-62-9 trans-4-hydroxycyclohexylamine 

Relevant articles and documents

IRAK INHIBITORS AND USES THEREOF

The present invention relates to compounds and methods useful for inhibiting one or more interleukin-l receptor-associated kinases ("IRAK"). In some embodiments, a provided compound inhibits IRAK-1 and IRAK-4. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.